| Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease. | |
| | |
MedLine Citation:
|
PMID: 20505518 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The aim of this study was to determine whether the addition of ezetimibe to ongoing statin therapy in patients with atherosclerosis and metabolic syndrome would favorably affect levels of inflammatory markers and adipokines. Individuals with the metabolic syndrome exhibit higher levels of inflammatory biomarkers and adipokines, which have been implicated in the pathobiology of cardiovascular risk. The impact of the addition of ezetimibe to statin therapy on these proinflammatory mediators is unclear. Fifty patients with metabolic syndrome and concomitant vascular disease receiving stable statin monotherapy, with low-density lipoprotein cholesterol (LDL-C) levels >77.4 mg/dL (>2.0 mM), were treated with ezetimibe 10 mg per day for 12 weeks. The primary study end point was the % change in adiponectin levels from baseline to 12 weeks. Secondary study end points included % changes in the levels of other circulating inflammatory markers, adipokines, and plasma lipids. The addition of ezetimibe to statin therapy resulted in a significant reduction in total cholesterol and LDL-C and the ratio of total cholesterol to high-density lipoprotein cholesterol. However, ezetimibe add-on treatment had no effect on the primary outcome of plasma adiponectin or on any of the secondary outcomes, including leptin, hsCRP, tumor necrosis factor-α, or interleukin-6 concentrations. These observations remained unchanged after adjusting for body mass index and for background statin used. The addition of ezetimibe to stable statin therapy in patients with vascular disease and metabolic syndrome, who were not at guideline recommended LDL-C levels, did not alter adipokine levels after 12 weeks. Short-term add-on with ezetimibe may not be associated with additional inflammatory benefits beyond improvements in cholesterol homeostasis. |
| | |
Authors:
|
Milan Gupta; Paul E Szmitko; Michelle Tsigoulis; Manoela F B Braga; Mahesh Kajil; Sheriar Herjikaka; Adrian Quan; Hwee Teoh; Subodh Verma |
Related Documents
:
|
7653448 - Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. 6847268 - Treatment of the arthropathy of familial hypercholesterolaemia. 12423708 - Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patie... 11693468 - Atorvastatin: an updated review of its pharmacological properties and use in dyslipidae... 15637308 - Identification of unique lipoprotein subclasses for visceral obesity by component analy... 3798368 - 6-mercaptopurine-induced alterations in mineral metabolism and teratogenesis in the rat. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of cardiovascular pharmacology Volume: 56 ISSN: 1533-4023 ISO Abbreviation: J. Cardiovasc. Pharmacol. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7902492 Medline TA: J Cardiovasc Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 241-5 Citation Subset: IM |
Affiliation:
|
Canadian Cardiovascular Research Network, Brampton, Ontario, Canada. mkgupta@rogers.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Two independent epidemics of HIV in Maryland.
Next Document: Mode of ethanol administration influences the severity of hemorrhage-induced lactic acidemia in cons...